Last 7 days
0.1%
Last 30 days
-4.7%
Last 90 days
-22.1%
Trailing 12 Months
-21.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 401.1B | 94.9B | -3.25% | -11.17% | 22.36 | 4.23 | 1.25% | -14.07% |
LLY | 302.8B | 28.5B | 2.15% | 17.94% | 48.48 | 10.61 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -3.99% | 33.34% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.5B | 100.3B | -4.70% | -21.30% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 143.9B | 46.2B | -5.09% | -4.47% | 22.74 | 3.12 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.6B | 4.5B | -7.51% | -10.48% | -32.41 | 1.02 | 7.56% | -104.06% |
RETA | 3.1B | 2.2M | 88.62% | 133.17% | -10.04 | 1.4K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -7.26% | 10.85% | 31.38 | 2.86 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -7.75% | -62.41% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -20.50% | -75.95% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 785.3M | 285.2M | -7.87% | -42.24% | 3.57 | 2.75 | -27.21% | -40.28% |
CRON | 738.3M | 114.5M | -10.60% | -51.38% | -4.38 | 6.45 | 27.90% | 57.40% |
ACRS | 534.2M | 29.8M | -36.88% | -54.59% | -6.15 | 17.95 | 340.05% | 4.35% |
OCUL | 379.8M | 51.5M | -18.81% | -6.64% | -5.35 | 7.38 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.5% | 100,330 | 99,879 | 101,276 | 92,433 | 81,288 |
S&GA Expenses | 4.1% | 13,677 | 13,136 | 12,644 | 12,519 | 12,703 |
EBITDA | 4.2% | 36,171 | 34,708 | 33,956 | 34,344 | - |
EBITDA Margin | 3.7% | 0.36* | 0.35* | 0.34* | 0.37* | - |
Earnings Before Taxes | 4.2% | 34,729 | 33,325 | 32,167 | 27,669 | 24,311 |
EBT Margin | 3.7% | 0.35* | 0.33* | 0.32* | 0.30* | - |
Interest Expenses | 4.3% | 1,442 | 1,383 | 1,440 | 1,475 | 1,467 |
Net Income | 5.4% | 31,372 | 29,771 | 29,309 | 24,966 | 21,979 |
Net Income Margin | 4.9% | 0.31* | 0.30* | 0.29* | 0.27* | - |
Free Cahsflow | 11.4% | 26,031 | 23,362 | 28,443 | 31,783 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.0% | 197,000 | 195,000 | 195,290 | 183,841 | 181,000 |
Current Assets | -27.2% | 51,259 | 70,403 | 67,466 | 54,420 | 59,693 |
Cash Equivalents | -68.0% | 416 | 1,298 | 1,780 | 2,470 | 1,944 |
Inventory | -5.6% | 8,981 | 9,513 | 10,454 | 9,979 | 9,059 |
Net PPE | 5.4% | 16,274 | 15,441 | 15,244 | 15,109 | 14,882 |
Goodwill | 6346.0% | 51,375 | 797 | 49,891 | 50,211 | 49,208 |
Liabilities | -1.1% | 101,288 | 102,459 | 107,821 | 101,155 | 104,013 |
Current Liabilities | -4.9% | 42,138 | 44,314 | 47,410 | 39,268 | 42,671 |
LT Debt, Current | -0.2% | 2,560 | 2,566 | 1,276 | 260 | 1,636 |
LT Debt, Non Current | 0.8% | 32,884 | 32,629 | 34,294 | 35,656 | 36,000 |
Shareholder's Equity | 3.3% | 95,661 | 92,631 | 87,469 | 82,685 | 77,201 |
Retained Earnings | 2.2% | 125,656 | 122,967 | 116,608 | 111,193 | 103,394 |
Additional Paid-In Capital | 0.5% | 91,802 | 91,359 | 91,183 | 90,844 | 90,591 |
Accumulated Depreciation | -0.3% | 14,931 | 14,969 | 15,358 | 15,074 | - |
Shares Outstanding | 0.3% | 5,607 | 5,593 | 5,617 | - | - |
Minority Interest | -1.2% | 256 | 259 | 261 | 261 | 262 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 10.0% | 29,267 | 26,599 | 31,454 | 34,583 | 32,580 |
Share Based Compensation | -13.1% | 872 | 1,004 | 1,162 | 1,096 | 1,182 |
Cashflow From Investing | -13.1% | -15,783 | -13,959 | -23,408 | -20,232 | -22,546 |
Cashflow From Financing | -12.6% | -14,834 | -13,170 | -8,510 | -13,587 | -9,816 |
Buy Backs | 0% | 2,000 | 2,000 | 2,000 | 2,000 | 0.00 |
46.1%
6.5%
0%
Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.
7.2%
8.1%
6.8%
14.6%
FIve years rolling returns for Pfizer.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 2.73 | 2,991,590 | 17,741,600 | 0.50% |
2023-03-13 | Claro Advisors LLC | added | 7.02 | 130,979 | 2,972,980 | 0.97% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 3,878 | 23,878 | -% |
2023-03-10 | Financial Alternatives, Inc | new | - | 383,941 | 383,941 | 0.38% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -10.00 | 11,741,400 | 229,834,000 | 0.25% |
2023-03-10 | MATHER GROUP, LLC. | added | 5.48 | 507,782 | 2,670,780 | 0.05% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -0.01 | 393,224 | 2,696,220 | 0.42% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 11.08 | 665,852 | 2,723,850 | 0.22% |
2023-03-07 | Nordwand Advisors, LLC | new | - | 5,119,080 | 5,119,080 | 0.64% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -0.68 | 1,043,020 | 7,441,020 | 2.83% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.94% | 501,636,220 | SC 13G/A | |
Feb 07, 2023 | state street corp | 5.08% | 284,943,697 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.9% | 442,868,761 | SC 13G/A | |
Feb 14, 2022 | state street corp | 5.09% | 285,771,591 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.29% | 465,274,925 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.3% | 409,985,645 | SC 13G/A | |
Feb 12, 2021 | state street corp | 5.03% | 279,831,373 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 8.06% | 447,958,747 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 7.1% | 396,973,512 | SC 13G/A | |
Feb 13, 2020 | state street corp | 5.28% | 292,628,794 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 51.05 26.77% | 62.08 54.16% | 122.82 204.99% | 161.21 300.32% | 292.19 625.58% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 23, 2023 | 4/A | Insider Trading | |
Mar 23, 2023 | SC 13G/A | Major Ownership Report | |
Mar 22, 2023 | PX14A6G | PX14A6G | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 21, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | ARS | ARS | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 4 | Insider Trading | |
Mar 16, 2023 | DEF 14A | DEF 14A |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-15 | DAMICO JENNIFER B. | sold | -396,678 | 40.02 | -9,912 | svp & controller |
2023-02-27 | SAHNI PAYAL | sold (taxes) | -52,891 | 40.78 | -1,297 | executive vice president |
2023-02-27 | DAMICO JENNIFER B. | sold (taxes) | -58,193 | 40.78 | -1,427 | svp & controller |
2023-02-27 | McDermott Michael | sold (taxes) | -125,643 | 40.78 | -3,081 | executive vice president |
2023-02-25 | SAHNI PAYAL | acquired | 204,202 | 22.89 | 8,921 | executive vice president |
2023-02-25 | DAMICO JENNIFER B. | acquired | 255,224 | 22.89 | 11,150 | svp & controller |
2023-02-25 | SUSMAN SALLY | acquired | 1,670,600 | 22.89 | 72,984 | executive vice president |
2023-02-25 | BOURLA ALBERT | sold (taxes) | -1,812,740 | 41.75 | -43,419 | chairman & ceo |
2023-02-25 | McDermott Michael | sold (taxes) | -392,417 | 42.9153 | -9,144 | executive vice president |
2023-02-25 | LANKLER DOUGLAS M | sold (taxes) | -1,101,740 | 41.75 | -26,389 | executive vice president |
Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||||||||||
Income Statement [Abstract] | |||||||||||||
Revenues | $ 100,330 | $ 81,288 | $ 41,651 | ||||||||||
Costs and expenses: | |||||||||||||
Cost of sales | [1] | 34,344 | 30,821 | 8,484 | |||||||||
Selling, informational and administrative expenses | [1] | 13,677 | 12,703 | 11,597 | |||||||||
Research and development expenses | [1] | 11,428 | 10,360 | 8,709 | |||||||||
Acquired in-process research and development expenses | [2] | 953 | 3,469 | 684 | |||||||||
Amortization of intangible assets | 3,609 | 3,700 | 3,348 | ||||||||||
Restructuring charges and certain acquisition-related costs | 1,375 | 802 | 579 | ||||||||||
Other (income)/deductions––net | 217 | (4,878) | 1,213 | ||||||||||
Income from continuing operations before provision/(benefit) for taxes on income | [3],[4],[5] | 34,729 | 24,311 | 7,036 | |||||||||
Provision/(benefit) for taxes on income | 3,328 | 1,852 | 370 | ||||||||||
Income from continuing operations | 31,401 | 22,459 | 6,666 | ||||||||||
Discontinued operations––net of tax | 6 | (434) | 2,529 | ||||||||||
Net income before allocation to noncontrolling interests | 31,407 | 22,025 | 9,195 | ||||||||||
Less: Net income attributable to noncontrolling interests | 35 | 45 | 36 | ||||||||||
Net income attributable to Pfizer Inc. common shareholders | $ 31,372 | $ 21,979 | $ 9,159 | ||||||||||
Earnings per common share––basic: | |||||||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | $ 5.59 | $ 4.00 | $ 1.19 | ||||||||||
Discontinued operations––net of tax (in dollars per share) | 0 | (0.08) | 0.46 | ||||||||||
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 5.59 | 3.92 | 1.65 | ||||||||||
Earnings per common share––diluted: | |||||||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 5.47 | 3.93 | 1.18 | ||||||||||
Discontinued operations––net of tax (in dollars per share) | 0 | (0.08) | 0.45 | ||||||||||
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | $ 5.47 | $ 3.85 | $ 1.63 | ||||||||||
Weighted-average shares––basic | 5,608 | 5,601 | 5,555 | ||||||||||
Weighted-average shares––diluted | 5,733 | 5,708 | 5,632 | ||||||||||
|
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 | ||||||
---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Cash and cash equivalents | $ 416 | $ 1,944 | ||||||
Short-term investments | 22,316 | 29,125 | ||||||
Trade accounts receivable, less allowance for doubtful accounts: 2022—$449; 2021—$492 | 10,952 | 11,479 | ||||||
Inventories | [1] | 8,981 | 9,059 | |||||
Current tax assets | 3,577 | 4,266 | ||||||
Other current assets | 5,017 | 3,820 | ||||||
Total current assets | 51,259 | 59,693 | ||||||
Equity-method investments | 11,033 | 16,472 | ||||||
Long-term investments | 4,036 | 5,054 | ||||||
Property, plant and equipment | 16,274 | 14,882 | ||||||
Identifiable intangible assets | [2] | 43,370 | 25,146 | |||||
Goodwill | [3] | 51,375 | 49,208 | |||||
Noncurrent deferred tax assets and other noncurrent tax assets | 6,693 | 3,341 | ||||||
Other noncurrent assets | 13,163 | 7,679 | ||||||
Total assets | 197,205 | 181,476 | ||||||
Liabilities and Equity | ||||||||
Short-term borrowings, including current portion of long-term debt: 2022—$2,560; 2021—$1,636 | 2,945 | 2,241 | ||||||
Trade accounts payable | 6,809 | 5,578 | ||||||
Dividends payable | 2,303 | 2,249 | ||||||
Income taxes payable | 1,587 | 1,266 | ||||||
Accrued compensation and related items | 3,407 | 3,332 | ||||||
Deferred revenues | 2,520 | 3,067 | ||||||
Other current liabilities | 22,568 | 24,939 | ||||||
Total current liabilities | 42,138 | 42,671 | ||||||
Long-term debt | 32,884 | 36,195 | ||||||
Pension and postretirement benefit obligations | 2,250 | 3,724 | ||||||
Noncurrent deferred tax liabilities | 1,023 | 349 | ||||||
Other taxes payable | 9,812 | 11,331 | ||||||
Other noncurrent liabilities | 13,180 | 9,743 | ||||||
Total liabilities | 101,288 | 104,013 | ||||||
Commitments and Contingencies | ||||||||
Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2022 and December 31, 2021 | 0 | 0 | ||||||
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2022—9,519; 2021—9,471 | 476 | 473 | ||||||
Additional paid-in capital | 91,802 | 90,591 | ||||||
Treasury stock, shares at cost: 2022—3,903; 2021—3,851 | (113,969) | (111,361) | ||||||
Retained earnings | 125,656 | 103,394 | ||||||
Accumulated other comprehensive loss | (8,304) | (5,897) | ||||||
Total Pfizer Inc. shareholders’ equity | 95,661 | 77,201 | ||||||
Equity attributable to noncontrolling interests | 256 | 262 | ||||||
Total equity | 95,916 | 77,462 | ||||||
Total liabilities and equity | $ 197,205 | $ 181,476 | ||||||
|